Complement-Protected Amphotropic Retroviruses from Murine Packaging Cells

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Human Gene Therapy

• Publication date

  1999-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/10430349950017572PMID 10446929
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Membrane proteins that protect against complement lysis

  2005cited by this paper
• The Entire SU Subunit is Required for the Incorporation of the HIV-1 Envelope Glycoprotein Complex into Virions

  2004cited by this paper
• Progress with retroviral gene vectors

  2000cited by this paper
• Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications

  2000cited by this paper
• FUT-175, a Synthetic Inhibitor of the Complement Pathway, Protects Against the Inactivation of Infectious Retroviruses by Human Serum

  1997cited by this paper
• Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.

  1997cited by this paper
• The α-Galactosyl Epitope: A Sugar Coating That Makes Viruses and Cells Unpalatable

  1996cited by this paper
• The alpha-galactosyl epitope: a sugar coating that makes viruses and cells unpalatable.

  1996cited by this paper
• Development of Amphotropic Murine Retrovirus Vectors Resistant to Inactivation by Human Serum

  1996cited by this paper
• A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety.

  1996cited by this paper
• Sensitization of cells and retroviruses to human serum by (αl-3) galactosyltransferase

  1996cited by this paper
• Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response

  1996cited by this paper
• Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase.

  1996cited by this paper
• The Effects of Human Serum and Cerebrospinal Fluid on Retroviral Vectors and Packaging Cell Lines

  1995cited by this paper
• Retroviral retargeting by envelopes expressing an N-terminal binding domain

  1995cited by this paper
• A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex.

  1995cited by this paper
• How glycosylphosphatidylinositol-anchored membrane proteins are made.

  1995cited by this paper
• Infectious Retrovirus Is Inactivated by Serum but Not by Cerebrospinal Fluid or Fluid from Tumor Bed in Patients with Malignant Glioma

  1995cited by this paper
• A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody

  1995cited by this paper
• High-titer packaging cells producing recombinant retroviruses resistant to human serum

  1995influential reference
• Protection of Retroviral Vector Particles in Human Blood Through Complement Inhibition

  1995cited by this paper
• Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell

  1994cited by this paper
• Intrathecal gene therapy for malignant leptomeningeal neoplasia.

  1994cited by this paper
• Galα(1,3)Gal, the Major Xenoantigen(s) Recognised in Pigs by Human Natural Antibodies

  1994cited by this paper
• Gene Therapy for the Treatment of Malignant Brain Tumors with In Vivo Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene/Ganciclovir System. Iowa Methodist Medical Center, Des Moines, Iowa

  1994cited by this paper
• Screening retroviral packaging cells for highly efficient virus production by using a combined selection procedure

  1994cited by this paper
• Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system.

  1994cited by this paper
• Dicistronic transcription units for gene expression in mammalian cells.

  1993cited by this paper
• Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with the Thymidine Kinase Gene and Intravenous Ganciclovir. National Institutes of Health

  1993cited by this paper
• In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats.

  1993cited by this paper
• Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir.

  1993cited by this paper
• Gene therapy of maliganant brain tumors: A rat glioma line bearing the herpes simplex virus type 1‐thymidine kinase gene and wild type retrovirus kills other tumor cells

  1992cited by this paper
• In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

  1992cited by this paper
• Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype

  1991cited by this paper
• Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys.

  1991cited by this paper
• Phospholipid-anchored and transmembrane versions of either decay- accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage

  1991cited by this paper
• Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells.

  1988cited by this paper
• Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges.

  1988cited by this paper
• Two dominant-acting selectable markers for gene transfer studies in mammalian cells.

  1988cited by this paper
• A new dominant hybrid selective marker for higher eukaryotic cells.

  1981cited by this paper
• Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway

  1976cited by this paper
• Inactivation of lysis of oncornaviruses by human serum.

  1976cited by this paper
• Human serum lyses RNA tumour viruses

  1975cited by this paper

• Envelope glycoproteins of vesiculoviruses : characteristics of antibody interactions and immunogenicity

  2018cites this paper
• Gene delivery and gene expression in vertebrate using baculovirus Bombyx mori nucleopolyhedrovirus vector

  2017cites this paper
• Controlled Gene Delivery Systems for Articular Cartilage Repair

  2017cites this paper
• Viral Gene Therapy Vectors

  2014cites this paper
• Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors

  2013cites this paper
• Host cells and cell banking.

  2011cites this paper
• Viral Vectors for Gene Therapy

  2011cites this paper
• Integrated Strategy for the Production of Therapeutic Retroviral Vectors

  2011cites this paper
• Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

  2010cites this paper
• La terapia genica nella riparazione cartilaginea

  2009cites this paper
• Novo Convertase Assembly Surfaces and Providing a Platform for De Activation by Binding Specific Target Properdin Can Initiate Complement

  2007cites this paper
• Properdin Can Initiate Complement Activation by Binding Specific Target Surfaces and Providing a Platform for De Novo Convertase Assembly1

  2007cites this paper
• Gene therapeutic approaches-transfer in vivo.

  2006cites this paper
• Epigenetic silencing and tissue independent expression of a novel tetracycline inducible system in double‐transgenic pigs

  2006influential citation
• A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors.

  2006cites this paper
• In Vivo Correction of Complement Regulatory Protein Deficiency with an Inhibitor Targeting the Red Blood Cell Membrane1

  2005cites this paper
• MembraneInhibitor Targeting the Red Blood Cell Regulatory Protein Deficiency with an In Vivo Correction of Complement

  2005cites this paper
• Establishment of murine cell lines by constitutive and conditional immortalization.

  2005cites this paper
• Baculovirus GP64-pseudotyped HIV-based lentivirus vectors are stabilized against complement inactivation by codisplay of decay accelerating factor (DAF) or of a GP64-DAF fusion protein.

  2005cites this paper
• Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation

  2005cites this paper
• Transcriptionally regulated immortalization overcomes side effects of temperature-sensitive SV40 large T antigen.

  2005cites this paper
• ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement.

  2004cites this paper
• Transcriptional control of SV40 T-antigen expression allows a complete reversion of immortalization.

  2004cites this paper
• Stable and strictly controlled expression of LTR-flanked autoregulated expression cassettes upon adenoviral transfer.

  2004cites this paper
• Green Fluorescent Protein-Tagged Retroviral Envelope Protein for Analysis of Virus-Cell Interactions

  2003cites this paper
• Retrovectors Go Forward

  2003cites this paper
• Vital marking of articular chondrocytes by retroviral infection using green fluorescence protein.

  2002cites this paper
• Development and use of viral vectors for gene transfer: lessons from their applications in gene therapy

  2002cites this paper
• The role of the complement system in virus infections.

  2001cites this paper
• Efficient transfer and expression of human clotting factor IX cDNA in neonatal hemophilia B mice mediated by VSV-G pseudotyped retrovirus

  2001cites this paper
• CYTOMEGALOVIRUS EARLY PROMOTER INDUCED EXPRESSION OF hCD59 IN PORCINE ORGANS PROVIDES PROTECTION AGAINST HYPERACUTE REJECTION1

  2001cites this paper
• Retroviral vectors for the transduction of autoregulated, bidirectional expression cassettes.

  2001cites this paper
• Progress with retroviral gene vectors

  2000cites this paper
• VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum.

  2000cites this paper
• Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications

  2000cites this paper
• Neuartige retrovirale Vektorsysteme für die Gentherapie: Entwicklung in Suspension wachsender Verpackungszellinien

  2000cites this paper
• Epigenetic Silencing and Tissue Independent Expression of a Novel Tetracycline Inducible System in Double- Transgenic Pigs 3. Enhanced Tissue-independent Expression of Cd59 in Crossbred Animals Carrying Two Nta-rca Cassettes

  year unknowncites this paper